Advertisement

Prostate Cancer

  • K. Pummer
  • P. Pürstner
  • G. Lanzer
  • U. Pätzold
  • H. L. Auner
Conference paper
Part of the ESO Monographs book series (ESO MONOGRAPHS)

Abstract

Adenocarcinoma of the prostate is one of the most common visceral cancers in males. It was estimated that in 1992 132,000 new cases were diagnosed in the United States and 34,000 prostatic cancer deaths occurred [1]. At the time of presentation, more than 50% of newly diagnosed patients either have locally advanced or metastatic disease. It is also widely recognised, however, that the prevalence of prostatic cancer found at autopsy largely surpasses the prevalence of clinically detectable disease [2]. In simple terms, there is a 14-fold greater risk of developing prostate cancer than there is of dying from it [31.

Keywords

Prostate Cancer Natural Killer Prostate Specific Antigen Natural Killer Activity Estramustine Phosphate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Boring CC, Squires TS, Tong T: Cancer statistics. Ca-A Cancer J Phys 1992 (42):19–38Google Scholar
  2. 2.
    Edwards CW, Steinthorsson E, Nicholson D: An autopsy study of latent prostatic cancer. Cancer 1953 (6):531–554Google Scholar
  3. 3.
    Scardino PT: Early detection of prostate cancer. Urol Clin N Am 1989 (16):635–655Google Scholar
  4. 4.
    Hanash KA: Natural history of prostatic cancer. In: Murphy GP, Khoury S, Küss R, Chatelain C, Denis L (eds) Progress in Clinical and Biological Research. Alan R Liss Inc, New York 1987 (Vol 243 B) pp 289–320Google Scholar
  5. 5.
    Veterans Administration Cooperative Urological Research Group (VACURG): Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 1967 (124):1011–11017Google Scholar
  6. 6.
    Huggins C, Hodges CV: Studies of prostatic cancer: I. Effect of castration, estrogen and androgen injections on serum phosphatase in metastatic carcinoma of the prostate. Cancer Res 1941 (1):293–297Google Scholar
  7. 7.
    Labrie F, DuPont A, Belanger A: Complete androgen blockade for the treatment of prostate cancer. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds) Important Advances in Oncology. JB Lippincott, Philadelphia 1985 pp 193–217Google Scholar
  8. 8.
    Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, Goodman PJ: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989 (321):419–424Google Scholar
  9. 9.
    Isaacs JT: The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer. The Prostate 1984 (5):1–17Google Scholar
  10. 10.
    Pummer K: Epirubicin plus flutamide and orchidectomy in previously untreated advanced prostatic cancer. Seminars in Oncology 1991 (18, suppl 6):26–28PubMedGoogle Scholar
  11. 11.
    Balkwill FR: Interferons. In: Cytokines in Cancer Therapy. Oxford University Press, Oxford 1989 pp 8–53Google Scholar
  12. 12.
    Gonor SE, Lakey WH, McBlain WA: Relationship between concentrations of extractable and matrix-bound nuclear androgen receptor and clinical response to endocrine therapy for prostatic adenocarcinoma. J Urol 1984 (131):1196–1201Google Scholar
  13. 13.
    Katzenellenbogen BS, Kendra KL, Norman MJ, Berthois Y: Proliferation, hormonal responsiveness, and estrogen receptor content of MCF-7 human breast cancer cells grown in the short-term and long-term absence of estrogens. Cancer Res 1987 (47):4355–4360Google Scholar
  14. 14.
    King RJB: Receptors, growth factors and steroid insensitivity of tumours. J Endocrinol 1990 (124):179–181Google Scholar
  15. 15.
    Trapman J, Brinkmann AO: Properties and expression of the androgen receptor in prostate cancer. In: Berns PMJJ, Romijn JC, Schröder FH (eds) Mechanism of Progression to Hormone-Independent Growth of Breast and Prostatic Cancer. Casterton Hall, Carnforth, The Parthenon Publishing Group Limited, Lanes 1991 pp 153–168Google Scholar
  16. 16.
    Ekman P, Brolin J: Steroid receptor profile in human prostate cancer metastases as compared with primary prostatic carcinoma. The Prostate 1991 (18):147–153Google Scholar
  17. 17.
    van den Berg HW, Leahey WJ, Lynch M, Clarke R, Nelson J: Recombinant human interferon alpha increases oestrogen receptor expression in human breast cancer cells (ZR-75-1 ) and sensitizes them to the antiproliferative effects of tamoxifen. Br J Cancer 1987 (55):255–257Google Scholar
  18. 18.
    Sica G, Natoli V, Stella C, Del Bianco S: Effect of natural beta-interferon on cell proliferation and steroid receptor level in human breast cancer cells. Cancer 1987 (60):2419–2423Google Scholar
  19. 19.
    Kangas L, Nieminen AL, Cantell K: Additive and synergistic effects of a novel antiestrogen, toremifene (Fc-1157a), and human interferons on estrogen responsive MCF-7 cells in vitro. Med Biol 1985 (63):187–190Google Scholar
  20. 20.
    Goldstein D, Bushmeyer SM, Witt PL, Jordan VC, Borden EC: Effects of type I and II interferons on cultured human breast cells: Interaction with estrogen receptors and with tamoxifen. Cancer Res 1989(49)2698–2702Google Scholar
  21. 21.
    Sica G, Fabbroni L, Dell’Acqua G, Iacopino F, Marchetti P, Cacciatore M, Pavone-Macaluso M: Natural ß-lnterferon and androgen receptors in prostatic cancer cells. Urol Int 1991 (46):159–162Google Scholar
  22. 22.
    Kaighn ME, Shankar Narayan K, Ohnuki Y, Lechner JF, Jones LW: Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 1979 (17):16–23Google Scholar
  23. 23.
    Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF: Isolation of a human prostate carcinoma cell line (DU-145). Int J Cancer 1978 (21):274–281Google Scholar
  24. 24.
    Krongrad A, Allman DR, Brothman AR, McPhaul MJ: The expression of the human androgen receptor (AR) in an androgen unresponsive human prostate cancer cell line (PPC-1) is insufficient to confer androgen responsiveness. J Urol (Abstr LXXXVIth AUA Annual Meeting, Toronto 1991) 1991 (145):295AGoogle Scholar
  25. 25.
    Borden EC, Balkwill FR: Preclinical and clinical studies of interferons and interferon inducers in breast cancer. Cancer 1984 (53):783–788Google Scholar
  26. 26.
    Borden EC, Groveman DS, Nasu T, Dernikoff C, Bryan GT: Antiproliferative activities of interferons against human bladder carcinoma cell lines in vitro. J Urol 1984 (132):800–803Google Scholar
  27. 27.
    Creasey AA, Bartholomew JL, Merigan TL: Role of G0-G1 arrest in the inhibition of tumour cell growth by interferon. Proc Natl Acad Sci USA 1980:1471–1475Google Scholar
  28. 28.
    Epstein L, Shen JT, Abele JS, Reese CC: Sensitivity of human ovarian carcinoma cells to interferon and other antitumour agents as assessed by an in vitro semi-solid agar technique. Ann NY Acad Sci 1980 (350):228–244Google Scholar
  29. 29.
    Fuse A, Kuwata T: Inhibition of DNA synthesis and alteration of cyclic adenosine 3′,5′ monophosphate levels in RSa cells by human leukocyte interferon. J Natl Cancer Inst 1978 (60):1227–1232Google Scholar
  30. 30.
    Tovey M, Rocheete-Egly C, Castagna M: Effect of interferon on concentrations of cyclic nucleotides in cultured cells. Proc Natl Acad Sci USA 1979 (76):3890–3893Google Scholar
  31. 31.
    Okutani T, Nishi N, Kagawa Y, Takasuga H, Takenaka I, Usui T, Wada F: Role of cyclic AMP and polypeptide growth regulators in growth inhibition by interferon in PC-3 ceils. The Prostate 1991 (18):73–80Google Scholar
  32. 32.
    Hayward S, Cox S, Mitchell I, Hallowes R, Desphande N, Towler J: The effects of interferons on the activity of glycerophosphate dehydrogenase in benign prostatic hyperplasia cells in primary culture. J Urol 1987(138):648–653Google Scholar
  33. 33.
    Desphande N, Mitchell I, Millis R: Tumour enzymes and prognosis in human breast cancer. Eur J Cancer 1981 (17):493–496Google Scholar
  34. 34.
    Kimchi A: Reduction of nuclear oncogene expression by endogenous and exogenous interferons. In: Smyth JD (ed) Interferons in Oncology. Springer Verlag, Berlin 1987 pp 53–65Google Scholar
  35. 35.
    Einat M, Resnitzky D, Kimchi A: Inhibitory effects of interferon on the expression of genes regulated by platelet-derived growth factor. Proc Natl Acad Sci USA 1985(82):7608–7612Google Scholar
  36. 36.
    Tovey MG: Interferon and cyclic nucleotides. Interferon 1982 (4):23–46Google Scholar
  37. 37.
    Schneck J, Ragen-Zisman B, Rosen OM, Bloom BR: Genetic analysis of the role of cAMP in mediating effect of interferon. Proc Natl Acad Sci USA 1982 (79):1879–1883Google Scholar
  38. 38.
    Weetman AP: Recombinant γ-interferon stimulates iodide uptake and cyclic AMP production by the FTRL5 thyroid cell line. FEBS Lett 1987 (221):91–94Google Scholar
  39. 39.
    Desphande N, Hallowes RC, Cox S, Mitchell I, Hayward S, Towler JM: Divergent effects of interferons on the growth of human benign prostatic hyperplasia cells in primary culture. J Urol 1989 (141):157–160Google Scholar
  40. 40.
    Sica G, Fabbroni L, Castagnetta L, Cacciatore M, Pavone-Macaluso M: Antiproliferative effect of interferons on human prostate carcinoma cell lines. Urol Res 1989 (17):111–115Google Scholar
  41. 41.
    Goldstein D, O’Leary M, Mitchen J, Borden EC, Wilding G: Effects of interferon-ßser and transforming growth factor ß on prostatic cell lines. J Urol 1991 (146):1173–1177Google Scholar
  42. 42.
    Van Moorselaar RJA, Beniers AJMC, Hendriks BT, Van Stratum P, Van der Meide PH, Debruyne FMJ, Schalken JA: In vivo antiproliferative effects of alpha-and gamma-interferon and tumor necrosis factor alpha on androgen-dependent and-independent prostatic tumors. J Urol (Abstr LXXXVth AUA Annual Meeting, New Orleans 1990) 1990(143):243AGoogle Scholar
  43. 43.
    Liu S, Ewing MW, Anglard P, Trahan E, La Rocca RV, Myers CE, Linehan WM: The effect of suramin, tumor necrosis factor and interferon-y on human prostate carcinoma. J Urol 1991 (145):389–392Google Scholar
  44. 44.
    La Rocca RV, Danesi R, Cooper MR, Jamis-Dow C, Ewing MW, Liu S, Linehan WM, Myers CE: Effect of suramin on human prostate cancer cells in vitro. J Urol 1991 (145):393–398Google Scholar
  45. 45.
    Zippe CD, Henry ET, Heston WDW, Fair WR: Antiproliferative effects of suramin, tumor necrosis factor and interferon-alpha on human prostatic carcinoma cell lines. J Urol (Abstr LXXXVth AUA Annual Meeting, New Orleans 1990) 1990 (143):241 AGoogle Scholar
  46. 46.
    Fidler IJ, Heicappell R, Saiki I, Grutter MG, Horisberger MA, Nuesch J: Direct antiproliferative effects of recombinant human interferon-alpha B/D hybrids on human tumor cell lines. Cancer Res 1987 (47):2020–2027Google Scholar
  47. 47.
    Schmid SM, Harrison SD, Cummings KB: Augmented anticellular effects of estramustine combined with interferon beta serine treatment for prostatic and renal carcinoma cells. J Urol (Abstr LXXXIVth AUA Annual Meeting, Dallas 1989) 1989 (141):518Google Scholar
  48. 48.
    Van Moorselaar RJA, Hendriks BT, Van Stratum P, Van der Meide P, Debruyne FMJ, Schalken JA: Synergistic antitumor effects of rat γ-interferon and human tumor necrosis factor alpha against androgen-dependent and-independent rat prostatic tumors. Cancer Res 1991 (51):2329–2334Google Scholar
  49. 49.
    Kyprianou N, English HF, Isaacs JT: Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res 1990 (50):3748–3753Google Scholar
  50. 50.
    Rubin BY, Smith LJ, Hellermann GR, Lunn RM, Richardson NK, Anderson SL: Correlation between the anticellular and DNA fragmentation activities of tumor necrosis factor. Cancer Res 1988 (48):6006–6010Google Scholar
  51. 51.
    Dealtry GB, Naylor MS, Fiers W, Baikwill FR: DNA fragmentation and cytotoxicity caused by tumor necrosis factor is enhanced by interferon-γ. Eur J Immunol 1987 (17):689–693Google Scholar
  52. 52.
    Van Moorselaar RJA, Van Stratum P, Borm G, Debruyne FMJ, Schalken JA: Differential antiproliferative activities of alpha-and gamma-interferon and tumor necrosis factor alone or in combinations against two prostate cancer xenografts transplanted in nude mice. The Prostate 1991 (18):331–344Google Scholar
  53. 53.
    Mickey DD, Carvalho L, Foulkes K: Combined therapeutic effects of conventional agents and an immunomodulator, PSK, on rat prostatic adenocarcinoma. J Urol 1989 (142):1594–1598Google Scholar
  54. 54.
    Romijn JC, Verkoelen CF, Schroeder FH: Measurement of the survival of human tumor cells after implantation in athymic nude mice. Int J Cancer 1986(38):97–101Google Scholar
  55. 55.
    Schwemmer B, Lehmer A, Hofmann R, Braun J: Natural killer cell activity in patients with prostatic carcinoma and its in vivo boosting with Bacillus Calmette-Guerin. Urol Int 1984 (39):321–326Google Scholar
  56. 56.
    Schmitz-Dräger BJ, Marumo K, Ackermann R: Kinetik der spontanen zellvermitteiten Zytotoxizität bei Patienten mit Prostatakarzinom. In: Harzmann R, Jacobi GH, Weissbach L (eds) Experimentelle Urologie. Springer Verlag, Berlin-Heidelberg 1985 pp 494–500Google Scholar
  57. 57.
    Choe BK, Frost P, Morrison MK, Rose NR: Natural killer cell activity of prostatic cancer patients. Cancer Investigation 1987 (5):285–291Google Scholar
  58. 58.
    Wirth M, Schmitz-Dräger BJ, Ackermann R: Functional properties of natural killer cells in carcinoma of the prostate. J Urol 1985 (133):973–978Google Scholar
  59. 59.
    Hanna N, Fidler IJ: Role of natural killer cells in the destruction of circulating tumor emboli. J Natl Cancer Inst 1980 (65):801–809Google Scholar
  60. 60.
    Gresser I: How does interferon inhibit tumor growth? Interferon 1985 (6):93–126Google Scholar
  61. 61.
    Wade AC, Schmidt MA, Pollard M: The relationship of natural killer cells to metastasis of transplantable prostate adenocarcinoma. The Prostate 1985 (7):53–61Google Scholar
  62. 62.
    Mizoguchi H, O’Shea JJ, Longo DL, Loeffler CM, McVicar DW, Ochoa AC: Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 1992 (258):1795–1798Google Scholar
  63. 63.
    Daar AS, Fuggle SV, Fabre JW, Ting A, Morris PJ: The detailed distribution of MHC class II antigens in normal human organs. Transplant 1984 (38):293–298Google Scholar
  64. 64.
    Bigotti G, Coli A, Castagnola D: Distribution of Langerhans cells and HLA class II molecules in prostatic carcinomas of different histopathological grade. The Prostate 1991 (19):73–87Google Scholar
  65. 65.
    Goldsmith NK, Dikman S, Bermas B, Davies TF, Roman SH: HLA class II antigen expression and the autoimmune thyroid response in patients with benign and malignant thyroid tumors. Clin Immunol Immunopathol 1988 (48):161–173Google Scholar
  66. 66.
    Natali PG, Bigotti A, Cavaliere R, Ruiter DJ, Ferrone S: HLA class II antigens synthesized by melanoma cells. Cancer Rev 1987 (9):1–34Google Scholar
  67. 67.
    Mullis KB and Faloona F: Specific synthesis of DNA in vitro via a polymerase-catalysed chain reaction. Methods Enzymol 1987 (155):335–350Google Scholar
  68. 68.
    Graham Jr SD, Metz R, Gal A, Manos S, Swerlick RA: Differential expression of ICAM-1 expression in BPH and prostatic adenocarcinoma. J Urol (LXXXVIth AUA Annual Meeting, Toronto 1991) 1991 (145):350AGoogle Scholar
  69. 69.
    Smyth JF: Guidelines for the use of INTRON A (interferon alpha-2B) in clinical oncology: lessions from the laboratory. Cancer Treat Rev 1988 (15):3–6Google Scholar
  70. 70.
    Laszlo J, Huang AT, Brenckman WD, Jeffs C, Koren H, Cianciolo G, Metzgar R, Cashdollar W, Cox E, Buckley III CE, Tso CY, Lucas Jr VS: Phase I study of pharmacological and immunological effects of human lymphoblastoid interferon given to patients with cancer. Cancer Res 1983 (43).4458–4466Google Scholar
  71. 71.
    Creagan ET, Frytak S, Long HJ, Kvols LK: Phase I study of recombinant leukocyte A interferon (IFN-alpha2A, Roferon-A) with doxorubicin in advanced malignant disease. Cancer 1989 (64):1034–1037Google Scholar
  72. 72.
    Chang AYC, Fisher HAG, Spiers ASD, Boros L: Toxicities of human recombinant interferon-alpha2 in patients with advanced prostate carcinoma. J Interferon Res 1986 (6):713–715Google Scholar
  73. 73.
    Van Haelst-Pisani C, Richardson RL, Thorneau TM, Hahn RG, Burch PA, Buckner JC, Frytak S: Phase II study of recombinant leukocyte A human interferon Roferon-A (IFL-RA) in patients with advanced hormone-resistant prostate cancer. Am Soc Clin Oncol (ASCO), Washington, DC 1990Google Scholar
  74. 74.
    Gutterman J, Quesada J: Clinical investigation of partially pure and recombinant DNA derived leukocyte interferon in human cancer. Tex Rep Biol Med 1981-1982 (41):626–633Google Scholar
  75. 75.
    Peddinani MV, Savery F: Human leukocyte interferon in the treatment of selected cancer patients. Clin Ther 1983(5):336–341Google Scholar
  76. 76.
    Medenica R, Slack N: Clinical results of leukocyte interferon-induced tumor regression in resistant human metastatic cancer resistant to chemotherapy and/or radiotherapy — pulse therapy schedule. Cancer Drug Deliv 1985 (2):53–76Google Scholar
  77. 77.
    Goldschmidt AJW, Bauer L, Tunn UW: “Third-line”-Therapie des metastasierten Prostatakarzinoms mit Interferon. In: Hofstetter A, Staehler G, Kriegmair M, Schuth J (eds) Zytokine in der Urologischen Onkologie. W. Zuckschwerdt Verlag, München 1990 pp 73–82Google Scholar
  78. 78.
    Taylor CW, Modiano MR, Woodson ME, Marcus SG, Alberts DS, Hersh EM: A phase I trial of fluorouracil, leucovorin, and recombinant interferon alpha-2b in patients with advanced malignancy. Seminars in Oncology 1992 (19, suppl 3): 185–190Google Scholar
  79. 79.
    Dreicer R, Forest P, Williams RD: A phase II study of 5-fluorouracil (5FU) and alpha interferon in hormone-refractory metastatic prostate cancer. Proc ASCO 1992(11)205Google Scholar
  80. 80.
    Pigon R, Dillon LP, Hemingway IH, Gearing AJH: Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatants of cytokine activated cultured endothelial cells. Biochem Biophys Res Comm 1992 (187):584–589Google Scholar
  81. 81.
    Bulbul MA, Hüben RP, Murphy GP: lnterferon-ß treatment of metastatic prostate cancer. J Surg Oncol 1986 (33):231–233Google Scholar
  82. 82.
    Kosaki G, Tominaga T, Nakao I, Niitani H: Phase I clinical study of human recombinant interferon gamma on various cancers. Proc 14th Int Cancer Cong, Budapest 1986 (1): Abstr 2485Google Scholar
  83. 83.
    Brunda M, Rosenbaum D, Stern L: Inhibition of experimentally-induced murine metastases by recombinant alpha interferon: correlation between the modulatory effect of interferon treatment. Int J Cancer 1984 (34):421–426Google Scholar
  84. 84.
    Ramani P, Hart IR, Balkwill FR: The effect of interferon on experimental metastases in immunocompetent and immunodeficient mice. Int J Cancer 1986 (37):563–568Google Scholar
  85. 85.
    Horn Y, Zeidman JL, Heller A, Hacohen D, Salzberg S: Serum interferon as a biological marker in malignant tumors. Oncology 1985 (42):164–168Google Scholar
  86. 86.
    Kita M, Nakagawa S, Watanabe H, Kitoh I, Yamaji M, Kishida T, Imanishi J: Interferon production capacity in patients with prostatic cancer: prognostic value. C R Soc Biol 1990 (184):181–186Google Scholar
  87. 87.
    Erlacher L, Gisslinger H, Chott A: Low dosage long-term treatment with recombinant alpha interferon induces in hairy cell leukemia continuous complete remission. Wien Klin Wochenschr 1991 (103):588–590Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1994

Authors and Affiliations

  • K. Pummer
    • 1
  • P. Pürstner
    • 2
  • G. Lanzer
    • 3
  • U. Pätzold
    • 3
  • H. L. Auner
    • 2
  1. 1.Universitätsklinik für UrologieKarl Franzens UniversitätGrazAustria
  2. 2.Universitätsklinik für Gynäkologie und GeburtshilfeKarl Franzens UniversitätGrazAustria
  3. 3.Department für Transfusionsmedizin und Immunhämatologie der Chirurgischen UniversitätsklinikKarl Franzens UniversitätGrazAustria

Personalised recommendations